कृपया अन्य खोज का प्रयास करें
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions. It has a bioproduction agreement with WuXi Biologics Limited to produce SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; and research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320. BioVaxys Technology Corp. is based in Vancouver, Canada.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
James Christopher Passin | 52 | 2016 | Co-Founder, CEO, Interim CFO, Interim Company Secretary & Director |
Kartik Chandran | - | 2021 | Member of Scientific Advisory Board |
Yvelise Barrios | - | 2021 | Scientific Adviser |
Adam Coutts | - | 2021 | Member of Advisory Board |
Shmuel Farhi | - | 2021 | Member of Scientific Advisory Board |
Charles J. Dunton | - | 2021 | Member of Advisory Board |
Craig William Loverock | 53 | 2022 | Independent Director |
Anthony John Guy Dutton | 67 | 2022 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है